Headlines

ALL NEWS

Next-generation sequencing mutational analysis of triple-negative breast cancer patients from matched FFPE and fresh frozen samples

Author(s): Mark Landers, Rhonda Meredith, Jerry Lee, Yipeng Wang, Byung-In Lee, Joseph Monforte; AltheaDx, San Diego, CA

Sub-category:  Triple Negative Breast Cancer

Category:  Breast Cancer – Triple-negative/Cytotoxics/Local Therapy

Meeting:  2012 ASCO Annual Meeting

Abstract No:  1058

Citation:  J Clin Oncol 30, 2012 (suppl; abstr 1058)

Abstract:

Background: TNBC is an aggressive subtype of breast cancer accounting for 10-15% of all cases. TNBC tumors (ER-/PR-/HER-) are more common in patients with BRCA mutations. BRCA mutations leading to homologous DNA repair deficient tumors enhance the efficacy of chemotherapy and PARP inhibitors. BRCA mutations have been identified in 20% of patients without family history. Identification of germline and somatic BRCA mutations in unselected patients could increase the number of patients who benefit from these therapies. Determining BRCA mutational status from FFPE and fresh frozen specimens may enable clinical studies in these patient populations.We describe the development of an NGS BRCA mutational assay compatible with FFPE and fresh frozen samples using tumor/adjacent normal matched tissues. Methods: Matched samples were purchased from Cureline. gDNA was isolated by lysis/column purification (Qiagen) and enriched for BRCA exons/flanking regions (Halogenomics Selector). Fragment libraries were constructed (Ion Torrent frag express) and prepared for sequencing by emPCR (Ion Torrent Template Xpress). Libraries were sequenced for 65 cycles (Ion Torrent PGM) yielding 2-4M reads/sample. Variants were called from tMAP aligned reads by GATK and VarScan. Overlapped exonic variants were filtered by p-value (<0.0001) from VarScan. Results: In the first patient set normalized average depth of BRCA exon coverage was 64X and 72X per 150K reads in FFPE and fresh frozen tissues respectively covering 95-100% of target. hg19 alignment rates varied between 97-99% across all samples. Similar numbers of variants were called in both FFPE (12) vs. fresh frozen (13) with a corresponding mean duplicate removed depth of coverage of 23.3X and 42.4X at the called positions. 10/13 calls in fresh frozen overlapped with those in FFPE. A tumor specific somatic frameshift insertion in BRCA2 was detected in both FFPE and fresh frozen tissues. Conclusions: Results indicate that NGS mediated BRCA mutational analysis demonstrates equivalent utility in both FFPE and fresh frozen tumor samples although more sequencing reads are required to produce equivalent depth of coverage starting from FFPE samples.

 

THE CLEARITY FOUNDATION PERSONALIZED MEDICINE IN ONCOLOGY SERIES: Payers and Physicians – A Help or Hindrance in Brining Personalized Medicine to Patients?

The second in The Clearity Foundation’s Personalized Medicine in Oncology Series will provide an interactive discussion of whether physicians and payers, who bridge the gap between technology developers and patients, are likely to be allies or antagonists in making personalized medicine a reality for patients. The panel will look at the commercial challenges of personalized medicine from both of these perspectives and will provide insights as to where opportunities exist for significant advances in patient outcomes.

Date & Time: Tuesday, May 22 2012; 5:00pm to 7:30pm

Venue: 10300 Campus Point Dr., Curie Room, San Diego

Registration: $50

RSVP: Please email patpio@clearityfoundation.org

Moderated by: Michael Pollock, Reynolds Pollock & Associates

Panelists:

Payer perspective:
Bryan Dechairo, MD, Senior Director, Head of Extramural R&D, Medco Research Institute

Physician perspective:
Bridgette Duggan, MD, Gynecologic Oncologist, Southcoast Gynecologic Oncology Inc.

The Clearity Foundation is the only foundation in America dedicated to improving therapeutic options for women with ovarian cancer now. We believe we are the first organization making personalized medicine a reality for women with this disease. By improving the information used in making treatment decisions, our goal is for women with ovarian cancer to live longer, healthier lives. More at www.clearityfoundation.org.

AltheaDx Certified as Authorized Customer Service Provider by Ion Torrent

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ — AltheaDx announced today that it has achieved authorized customer service provider (CSP) status in Ion Torrent’s new service provider program. The CSP certification formalizes AltheaDx’s extensive training and testing under the guidance of Ion Torrent personnel to produce the highest quality sequence data.

Ion Torrent has revolutionized DNA sequencing through their pioneering use of semiconductor technology and simple chemistry instead of light as an intermediary signal. Ion Torrent technology translates the chemical signals into digital information, massively increasing the speed and decreasing the cost of DNA sequencing, thus enabling applications in nucleic acid-based biomarker discovery and clinical trial support that have been heretofore unachievable.

Francois Ferre, Ph.D., CEO of AltheaDx commented that “Implementation of next-generation sequencing is a natural addition to AltheaDx’s suite of nucleic acid-based testing services, where for the past 14 years we have supported our pharma partners in over 450 studies. Furthermore, the speed and ease with which we can develop and validate new customized assay designs using the Ion Personal Genome Machine (PGM™) has completely changed our approach to supporting their translational biomarker development efforts.”

Joe Monforte, Ph.D., CSO, of AltheaDx added, “We are excited about the evolution of NGS platforms and their specific utility in the molecular pathology lab setting. We are already implementing this platform for use in clinical studies. The fact that LIFE has laid out a diagnostic path for the Ion Torrent device means that we can now push ahead several of our companion diagnostic programs based on NGS.”

Maneesh Jain, Vice President of Marketing and Business Development at Ion Torrent indicated that “AltheaDx was among our first early access sites and now we are very pleased to have them on board not just as an Ion Torrent Authorized Customer Service Provider for the Ion PGM, but as a partner who will help extend the boundaries of Next Generation Sequencing.”

About AltheaDx, Inc.:

AltheaDx, a leading San Diego-based diagnostic development and testing company, provides clinical biomarker discovery, assay development and validation services that support researchers worldwide in their efforts to utilize genomic information for the advancement of novel therapies. AltheaDx plays a critical role in helping pharma to discover and validate biomarkers that can predict drug response, and then to provide an efficient seamless commercialization path to bring the tests to market. The goal of AltheaDx is to reduce the time, risk, and cost of therapeutic development for pharma partners.

For more information, visit www.altheadx.com

About Life Technologies:

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies’ industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.

CONTACT: Steven Daniel, +1-760-532-9759, sdaniel@altheadx.com

SOURCE AltheaDx

Related Links:
http://www.altheadx.com
http://www.lifetechnologies.com

AltheaDx Launches NGS Mutation Panel Focused on DNA Repair and Homologous Recombination to Support Clinical Trials

In coordination with Gynecologic Oncology Group 84th Semi-Annual Meeting in San Diego this week, AltheaDx has announced the launch of a next-generation sequencing (NGS) service designed to support clinical trials in the detection of mutations in genes encoding components of DNA repair and homologous recombination pathways. Modulation of these pathways is a current therapeutic strategy for some gynecologic cancers.

In particular, poly [ADP-ribose] polymerase 1 (PARP1 ) plays a central role in repair of single-stranded DNA (ssDNA) breaks. Inhibiting PARP1 activity with small molecules reduces repair of ssDNA breaks. In the absence of PARP1, when these breaks are encountered during DNA replication, the replication fork stalls, and double-strand DNA (dsDNA) breaks accumulate. These dsDNA breaks are repaired via homologous recombination (HR) repair. It is hypothesized that PARP1 inhibitors may prove highly effective as therapies for cancers with BRCA1/2 mutations, such as ovarian cancer, due to the high sensitivity of the tumors to the inhibitor and the lack of deleterious effects on the remaining healthy cells with functioning BRCA homologous recombination pathway. This is in contrast to conventional chemotherapies, which are highly toxic to all cells and can induce DNA damage in healthy cells, leading to secondary cancer generation.

AltheaDx provides NGS services using both the Life Technologies Ion Torrent PGM™ system and the Roche 454 GS Jr™ system with a total workflow solution starting from nucleic acid isolation, target enrichment, library construction and sequencing. The workflow exploits a NGS protocol that enriches for RefSeq defined UTR and exonic regions of genes encoding DNA repair and homologous recombination enzymes using targeted selection from genomic DNA. The digital nature and large dynamic range of targeted resequencing of clinical trial samples by NGS enables comparisons of genomic variations from both germline controls and tumor samples in order to identify tumor specific genetic variations (such as BRCA1/2 and RAD51 mutations) potentially aiding in the selection of clinical trial cohorts likely to respond to targeted therapeutics (such as PARP inhibitors).

Page 2 of 1112345...10...Last »